It Seems Affimed N.V. (NASDAQ:AFMD) Will Go Down. Just Reported More Shorted Shares

September 14, 2018 - By Kristin Houston

The stock of Affimed N.V. (NASDAQ:AFMD) registered an increase of 351.55% in short interest. AFMD’s total short interest was 1.39M shares in September as published by FINRA. Its up 351.55% from 307,300 shares, reported previously. With 6.91M shares average volume, it will take short sellers 0 days to cover their AFMD’s short positions. The short interest to Affimed N.V.’s float is 3.31%.

The stock decreased 3.23% or $0.15 during the last trading session, reaching $4.5. About 568,675 shares traded. Affimed N.V. (NASDAQ:AFMD) has risen 126.19% since September 14, 2017 and is uptrending. It has outperformed by 110.57% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $280.76 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 2 analysts covering Affimed (NASDAQ:AFMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Affimed has $5 highest and $4 lowest target. $4.50’s average target is 0.00% above currents $4.5 stock price. Affimed had 3 analyst reports since August 9, 2018 according to SRatingsIntel. BMO Capital Markets maintained Affimed N.V. (NASDAQ:AFMD) on Thursday, August 9 with “Outperform” rating. The rating was upgraded by Jefferies to “Buy” on Tuesday, August 28. The firm has “Outperform” rating given on Tuesday, August 28 by BMO Capital Markets.

Another recent and important Affimed N.V. (NASDAQ:AFMD) news was published by which published an article titled: “Affimed Therapeutics: Continued Upside Ahead” on August 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.